{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:39Z","timestamp":1789475559039,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":136,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100325","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T21:19:39Z","timestamp":1652908779000},"page":"100325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immunotherapy in indolent Non-Hodgkin's Lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Ghid","family":"Amhaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lrr.2022.100325_bib0001","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma","volume":"89","author":"Chan","year":"1997","journal-title":"Blood"},{"issue":"sup4","key":"10.1016\/j.lrr.2022.100325_bib0002","doi-asserted-by":"crossref","DOI":"10.1080\/10428190310001616917","article-title":"Traditional treatment approaches IN B-cell Non-Hodgkin's Lymphoma","volume":"44","author":"Zinzani","year":"2003","journal-title":"Leukemia & Lymphoma"},{"issue":"3","key":"10.1016\/j.lrr.2022.100325_bib0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-8140(95)01600-L","article-title":"Radiotherapy results in early stage low grade NODAL non Hodgkin's lymphoma","volume":"36","author":"Pendlebury","year":"1995","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"10.1016\/j.lrr.2022.100325_bib0004","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdx768","article-title":"Rituximab: A benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","volume":"29","author":"Karmali","year":"2021","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"11","key":"10.1016\/j.lrr.2022.100325_bib0005","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.V106.11.2428.2428","article-title":"Initial safety and EFFICACY results of a second generation humanized anti-CD20 Antibody, IMMU-106 (hA20), in Non-hodgkin's lymphoma","volume":"106","author":"Morschhauser","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2022.100325_bib0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-5-64","article-title":"Novel cd20 monoclonal antibodies for lymphoma therapy","volume":"5","author":"Cang","year":"2012","journal-title":"Journal of hematology & oncology"},{"key":"10.1016\/j.lrr.2022.100325_bib0007","unstructured":"Freedman, A. S. (1970, January 1). Pathology, Immunobiology, and natural history of NHL. Holland-Frei Cancer Medicine. 6th edition. Retrieved September 10, 2021, from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK13723\/."},{"issue":"1","key":"10.1016\/j.lrr.2022.100325_bib0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as Single first-line therapy for patients with follicular Lymphoma with a Low tumor burden: Clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lrr.2022.100325_bib0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02981940","article-title":"Re-treatment of relapsed indolent b-cell lymphoma with rituximab","volume":"73","author":"Igarashi","year":"2001","journal-title":"International Journal of Hematology"},{"issue":"20","key":"10.1016\/j.lrr.2022.100325_bib0010","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients With Indolent non-hodgkin's Lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1016\/j.lrr.2022.100325_bib0011","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and Molecular remission in patients with low-grade or Follicular Non-Hodgkin's Lymphoma treated With Rituximab plus CHOP chemotherapy: 9-Year Follow-Up","volume":"22","author":"Czuczman","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.lrr.2022.100325_bib0012","series-title":"Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma, Adis Data Information BV","author":"Fanale","year":"2007"},{"key":"10.1016\/j.lrr.2022.100325_bib0013","unstructured":"Dotan, E., Aggarwal, C., & Smith, M. R. (2010, March). Impact of Rituximab (Rituxan) on the treatment Of B-Cell Non-Hodgkin's Lymphoma. P & T: a peer-reviewed journal for formulary management. Retrieved September 10, 2021, from https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2844047\/."},{"issue":"10","key":"10.1016\/j.lrr.2022.100325_bib0014","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.lrr.2022.100325_bib0015","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine- rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2022.100325_bib0016","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bjh.17420","article-title":"A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A\u00a0+\u00a0B study)","volume":"193","author":"Rummel","year":"2021","journal-title":"Br. J. Haematol"},{"issue":"10","key":"10.1016\/j.lrr.2022.100325_bib0017","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.lrr.2022.100325_bib0018","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"Augment: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol"},{"issue":"9759","key":"10.1016\/j.lrr.2022.100325_bib0019","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to Rituximab Plus Chemotherapy (Prima): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"The Lancet"},{"issue":"18","key":"10.1016\/j.lrr.2022.100325_bib0020","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of Rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2022.100325_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hon.2438_74","article-title":"Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the Lyma trial conducted on behalf the Lysa Group","volume":"35","author":"Le Gouill","year":"2017","journal-title":"Hematological Oncology"},{"issue":"6","key":"10.1016\/j.lrr.2022.100325_bib0022","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: Prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.lrr.2022.100325_bib0023","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J. Clin. Oncol"},{"issue":"5","key":"10.1016\/j.lrr.2022.100325_bib0024","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br. J. Haematol"},{"issue":"5 Suppl 14","key":"10.1016\/j.lrr.2022.100325_bib0025","first-page":"88","article-title":"CHOP plus Rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Seminars in oncology"},{"key":"10.1016\/j.lrr.2022.100325_bib0026","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","article-title":"Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab","volume":"27","author":"Visser","year":"2013","journal-title":"BioDrugs"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2022.100325_bib0027","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2018-99-111248","article-title":"A randomized, double-blind efficacy and safety study of PF-05280586 (a potential rituximab biosimilar) compared with rituximab reference product (Mabthera\u00ae) in subjects with previously untreated CD20-positive, low tumor burden follicular lymphoma (LTB-FL)","volume":"132","author":"Sharman","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2022.100325_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-cd20 monoclonal antibodies for the treatment of b-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"issue":"1-2","key":"10.1016\/j.lrr.2022.100325_bib0029","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/10428199909145966","article-title":"Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenstr\u00f6m's macroglobulinaemia","volume":"36","author":"Weide","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.lrr.2022.100325_bib0030","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lrr.2022.100325_bib0031","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/cncr.21882","article-title":"Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma","volume":"106","author":"Tam","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.lrr.2022.100325_bib0032","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.lrr.2022.100325_bib0033","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.lrr.2022.100325_bib0034","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.lrr.2022.100325_bib0035","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lrr.2022.100325_bib0036","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+\u00a0autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"10044","key":"10.1016\/j.lrr.2022.100325_bib0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"9873","key":"10.1016\/j.lrr.2022.100325_bib0038","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lrr.2022.100325_bib0039","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.lrr.2022.100325_bib0040","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","article-title":"A phase 3 randomized study (HOMER) of Ofatumumab Vs rituximab in iNHL relapsed after rituximab-containing Therapy","volume":"4","author":"Maloney","year":"2020","journal-title":"Blood Advances"},{"issue":"11","key":"10.1016\/j.lrr.2022.100325_bib0041","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V110.11.645.645","article-title":"Interim results of a Phase i\/ii study of Ocrelizumab, a New Humanized Anti-CD20 antibody in patients with Relapsed\/Refractory Follicular Non-hodgkin's lymphoma","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.lrr.2022.100325_bib0042","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1182\/blood.V118.21.4982.4982","article-title":"Population pharmacokinetics study of a New Humanized Anti-cd20 monoclonal Antibody ame-133v (LY2469298) in patients with previously Treated Follicular lymphoma (fl)","volume":"118","author":"Cronier","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2022.100325_bib0043","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clim.2014.06.005","article-title":"A phase I study of Pro131921, a novel Anti-cd20 monoclonal antibody in patients with relapsed\/refractory Cd20+ Indolent Non-Hodgkin Lymphoma: Correlation between Clinicall responses and AUC Pharmacokinetics","volume":"154","author":"Casulo","year":"2014","journal-title":"Clinical Immunology"},{"issue":"7","key":"10.1016\/j.lrr.2022.100325_bib0044","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (ga101) PLUS chop or FC IN relapsed\/refractory follicular Lymphoma: Results of The GAUDI Study (bo21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.lrr.2022.100325_bib0045","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1714337","article-title":"Obinutuzumab treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"15_suppl","key":"10.1016\/j.lrr.2022.100325_bib0046","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.lba8502","article-title":"GADOLIN: Primary results from a phase III study OF obinutuzumab plus Bendamustine compared with Bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma","volume":"33","author":"Sehn","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1016\/j.lrr.2022.100325_bib0047","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.V128.22.2401.2401","article-title":"Evaluation of fatigue in previously untreated CLL patients with comorbidities treated with obinutuzumab (GA101)\u00a0+\u00a0chlorambucil (gclb) or Rituximab\u00a0+\u00a0Chlorambucil (RCLB)","volume":"128","author":"Goede","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2022.100325_bib0048","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/014107680509800403","article-title":"Therapeutic monoclonal antibodies in oncology","volume":"98","author":"Levene","year":"2005","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"12","key":"10.1016\/j.lrr.2022.100325_bib0049","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase i\/ii trial of idec-y2b8 radioimmunotherapy for treatment of relapsed or refractory cd20+ b-cell non-hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1016\/j.lrr.2022.100325_bib0050","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine i 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade b-cell non-hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.lrr.2022.100325_bib0051","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann. Oncol"},{"issue":"4","key":"10.1016\/j.lrr.2022.100325_bib0052","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/smim.1998.0121","article-title":"Cd22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor","volume":"10","author":"Sato","year":"1998","journal-title":"Seminars in Immunology"},{"issue":"22","key":"10.1016\/j.lrr.2022.100325_bib0053","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy With epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.lrr.2022.100325_bib0054","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-Fractionated Radioimmunotherapy IN Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized ANTI-CD22 monoclonal Antibody, epratuzumab","volume":"11","author":"Lind\u00e9n","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/j.lrr.2022.100325_bib0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V106.11.230.230","article-title":"Preliminary report of a Phase 1 study OF cmc-544, an antibody-targeted Chemotherapy agent, in patients With B-Cell non-hodgkin's Lymphoma (NHL)","volume":"106","author":"Advani","year":"2005","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.lrr.2022.100325_bib0056","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of Galiximab, An Anti-CD80 Antibody, For Relapsed or Refarctory Follicular Lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1016\/j.lrr.2022.100325_bib0057","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II trial of Brentuximab Vedotin for Cd30+ Cutaneous T-Cell lymphoma And Lymphomatoid Papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.lrr.2022.100325_bib0058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.36290\/xon.2018.024","article-title":"Brentuximab vedotin in the treatment of relapsed CD30 positive cutaneous lymphoma - results of an international, open label, randomised, phase 3, multicentre trial - alcanza","volume":"12","author":"Belada","year":"2018","journal-title":"Onkologie"},{"issue":"4","key":"10.1016\/j.lrr.2022.100325_bib0059","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome With alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"European Journal of Haematology"},{"issue":"8","key":"10.1016\/j.lrr.2022.100325_bib0060","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-cd52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral t-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2022.100325_bib0061","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"Cd40-cd40 ligand","volume":"67","author":"Kooten","year":"2000","journal-title":"JLB. J Leukoc Biol"},{"issue":"18","key":"10.1016\/j.lrr.2022.100325_bib0062","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-05-0095","article-title":"Preclinical Antilymphoma activity of a humanized ANTI-CD40 monoclonal antibody, sgn-40","volume":"65","author":"Law","year":"2005","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/j.lrr.2022.100325_bib0063","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjh.12630","article-title":"Phase ia\/ii, multicentre, open-label study of the cd40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-hodgkin or hodgkin lymphoma","volume":"164","author":"Fanale","year":"2013","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.lrr.2022.100325_bib0064","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.2147\/OTT.S219449","article-title":"Profile of Polatuzumab Vedotin in the treatment of patients with relapsed\/refractory Non-Hodgkin Lymphoma: A brief report on the Emerging Clinical Data","volume":"13","author":"Sawalha","year":"2020","journal-title":"OncoTargets and Therapy"},{"issue":"5","key":"10.1016\/j.lrr.2022.100325_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (romulus)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"The Lancet Haematology"},{"issue":"1","key":"10.1016\/j.lrr.2022.100325_bib0066","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: An emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.lrr.2022.100325_bib0067","doi-asserted-by":"crossref","unstructured":"Schuster S.J. et\u00a0al., Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Oral Abstracts #6. 2019 Dec 8. 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, FL, US.","DOI":"10.1182\/blood-2019-123742"},{"issue":"18","key":"10.1016\/j.lrr.2022.100325_bib0068","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"10306","key":"10.1016\/j.lrr.2022.100325_bib0069","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"The Lancet"},{"issue":"16","key":"10.1016\/j.lrr.2022.100325_bib0070","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.lrr.2022.100325_bib0071","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/lenalidomide in relapsed\/refractory non-Hodgkin's lymphoma: a phase i california cancer consortium study of safety, efficacy and immune correlative analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2022.100325_bib0072","doi-asserted-by":"crossref","unstructured":"Knobler, R., Faculty opinions recommendation of mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial. Faculty Opinions \u2013 Post-Publication Peer Review of the Biomedical Literature. (2020). 10.3410\/f.733808601.793573974.","DOI":"10.3410\/f.733808601.793573974"},{"key":"10.1016\/j.lrr.2022.100325_bib0073","doi-asserted-by":"crossref","unstructured":"Kreitman, R, Faculty opinions recommendation of phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. Faculty Opinions \u2013 Post Publication Peer Review of the Biomedical Literature. (2011). 10.3410\/f.8357958.8804055.","DOI":"10.3410\/f.8357958.8804055"},{"issue":"2","key":"10.1016\/j.lrr.2022.100325_bib0074","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","article-title":"Apoptosis control by death and decoy receptors","volume":"11","author":"Ashkenazi","year":"1999","journal-title":"Current Opinion in Cell Biology"},{"issue":"16_suppl","key":"10.1016\/j.lrr.2022.100325_bib0075","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1200\/jco.2005.23.16_suppl.6592","article-title":"Phase II trial of single Agent BEVACIZUMAB in patients with relapsed, Aggressive non-Hodgkin's Lymphoma (NHL): Southwest Oncology group StudyS0108","volume":"23","author":"Stopeck","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.lrr.2022.100325_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681984","article-title":"A deep insight into car-t cell therapy in non-hodgkin lymphoma: Application, opportunities, and future directions","volume":"12","author":"Marofi","year":"2021","journal-title":"Frontiers in Immunology"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:19Z","timestamp":1761959299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":76,"alternative-id":["S2213048922000371"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100325","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in indolent Non-Hodgkin's Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100325"}}